Vimarsana
Biggest News Aggregation in the World

Primer Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primer Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primer Capital Today - Breaking & Trending Today

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of February 28, 2023 - Vimarsana News

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of February 28, 2023

Published: March 3, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralDennis RiedlNewton BiocapitalVenture InvestmentFrench National Institute Of HealthRegulation Of The French Financial Markets AuthorityEuropean Medicines AgencyRegulatory NewsFrench Commercial CodeGeneral RegulationFrench Financial Markets AuthorityEuronext Growth ParisFrench National InstituteMedical ResearchActicor BiotechMirae Asset CapitalPrimer Capital
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023 - Vimarsana News

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023

Published: February 8, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralNewton BiocapitalSchwierige ZeitenVenture InvestmentFrench National Institute Of HealthRegulation Of The French Financial Markets AuthorityEuropean Medicines AgencyRegulatory NewsFrench Commercial CodeGeneral RegulationFrench Financial Markets AuthorityEuronext Growth ParisFrench National InstituteMedical ResearchActicor BiotechMirae Asset CapitalPrimer Capital
Acticor Biotech Announces the Appointment of Patricia Zilliox to the Board of Directors as an Indepe - Vimarsana News

Acticor Biotech Announces the Appointment of Patricia Zilliox to the Board of Directors as an Indepe

Published: February 6, 2023

PARIS--(BUSINESS WIRE)--Regulatory News:ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, is announcing today the appointment of Patricia Zilliox as a...

Source: pharmiweb.com
Related Topics:
United StatesFrance GeneralNewton BiocapitalCorinne Le GoffPatricia ZillioxAlain MunozVenture InvestmentFrench National Institute Of HealthEuropean Medicines AgencyFoundation Fighting BlindnessClinical Research InstituteRegulatory NewsActicor BiotechAnnual General MeetingSenior Director Clinical PharmaAlcon LaboratoriesFrench National InstituteMedical ResearchMirae Asset CapitalPrimer CapitalMediolanum FarmaceuticiEuronext Growth Paris
Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux - Vimarsana News

Acticor Biotech: Half-year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Published: January 6, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralNewton BiocapitalKepler CheuvreuxVenture InvestmentFrench National Institute Of HealthEuropean Medicines AgencyRegulatory NewsFrench National InstituteMedical ResearchActicor BiotechMirae Asset CapitalPrimer CapitalEuronext Growth Paris
Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2022 - Vimarsana News

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2022

Published: January 6, 2023

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies

Source: finanznachrichten.de
Related Topics:
France GeneralNewton BiocapitalVenture InvestmentFrench National Institute Of HealthRegulation Of The French Financial Markets AuthorityEuropean Medicines AgencyRegulatory NewsFrench Commercial CodeGeneral RegulationFrench Financial Markets AuthorityEuronext Growth ParisFrench National InstituteMedical ResearchActicor BiotechMirae Asset CapitalPrimer Capital